{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:35:22Z","timestamp":1793367322719,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Comprehensive Support Project for Oncology Research of Public Health Research Foundation"},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40273-017-0580-7","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T09:26:28Z","timestamp":1508232388000},"page":"215-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3792-5368","authenticated-orcid":false,"given":"Yasuhiro","family":"Hagiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Shiroiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Shimozuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"580_CR1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"580_CR2","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2014.56.7479","volume":"32","author":"AH Partridge","year":"2014","unstructured":"Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:3307\u201329.","journal-title":"J Clin Oncol"},{"key":"580_CR3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF01806751","volume":"1","author":"AHG Paterson","year":"1981","unstructured":"Paterson AHG, Szafran O, Cornish F, et al. Effect of chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat. 1981;1:357\u201363.","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 3","key":"580_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","volume":"10","author":"J O\u2019Shaughnessy","year":"2005","unstructured":"O\u2019Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20\u20139.","journal-title":"Oncologist"},{"key":"580_CR5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3322\/CA.2008.0008","volume":"58","author":"YC Shih","year":"2008","unstructured":"Shih YC, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin. 2008;58:231\u201344.","journal-title":"CA Cancer J Clin."},{"key":"580_CR6","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1016\/j.ejca.2006.08.010","volume":"42","author":"P Tappenden","year":"2006","unstructured":"Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006;42:2867\u201375.","journal-title":"Eur J Cancer"},{"key":"580_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-015-3383-6","volume":"151","author":"V Diaby","year":"2015","unstructured":"Diaby V, Tawk R, Sanogo V, et al. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 2015;151:27\u201340.","journal-title":"Breast Cancer Res Treat."},{"key":"580_CR8","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL. Cost-utility Analysis. In: Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL, editors. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.","edition":"3"},{"key":"580_CR9","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1200\/JCO.1999.17.10.3082","volume":"17","author":"PP Leung","year":"1999","unstructured":"Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol. 1999;17:3082\u201390.","journal-title":"J Clin Oncol."},{"key":"580_CR10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2165\/00019053-200119110-00003","volume":"19","author":"RE Brown","year":"2001","unstructured":"Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics. 2001;19:1091\u2013102.","journal-title":"Pharmacoeconomics."},{"key":"580_CR11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95:683\u201390.","journal-title":"Br J Cancer."},{"key":"580_CR12","first-page":"W17","volume":"7","author":"SM Grunberg","year":"2009","unstructured":"Grunberg SM, Weeks J, Magnan WF, et al. Determination of utility scores for control of chemotherapy-induced nausea or vomiting\u2014CALGB 309801. J Support Oncol. 2009;7:W17\u201320.","journal-title":"J Support Oncol."},{"key":"580_CR13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clinthera.2013.03.009","volume":"35","author":"GW Frederix","year":"2013","unstructured":"Frederix GW, Quadri N, H\u00f6vels AM. Utility and work productivity data for economic evaluation of breast cancer therapies in the Netherlands and Sweden. Clin Ther. 2013;35:e1\u20137.","journal-title":"Clin Ther."},{"key":"580_CR14","unstructured":"National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. https:\/\/www.nice.org.uk\/guidance\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 . Accessed 5 Jun 2017."},{"key":"580_CR15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jval.2010.10.015","volume":"14","author":"JC Tosh","year":"2011","unstructured":"Tosh JC, Longworth LJ, George E. Utility values in National Institute for Health and Clinical Excellence (NICE) technology appraisals. Value Health. 2011;14:102\u20139.","journal-title":"Value Health."},{"key":"580_CR16","first-page":"625","volume":"62","author":"T Fukuda","year":"2013","unstructured":"Fukuda T, Shiroiwa T, Ikeda S, et al. Guideline for economic evaluation of healthcare technologies in Japan (in Japanese). J Natl Inst Public Health. 2013;62:625\u201340.","journal-title":"J Natl Inst Public Health"},{"key":"580_CR17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","volume":"20","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an official guideline for the economic evaluation of drugs\/medical devices in Japan. Value Health. 2017;20:372\u20138.","journal-title":"Value Health."},{"key":"580_CR18","doi-asserted-by":"crossref","first-page":"e0124169","DOI":"10.1371\/journal.pone.0124169","volume":"10","author":"T Tachi","year":"2015","unstructured":"Tachi T, Teramachi H, Tanaka K, et al. The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS One. 2015;10:e0124169.","journal-title":"PLoS One."},{"key":"580_CR19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11136-016-1388-1","volume":"26","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Shimozuma K, et al. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res. 2017;26:445\u201353.","journal-title":"Qual Life Res."},{"key":"580_CR20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1470-2045(15)00411-8","volume":"17","author":"T Takashima","year":"2016","unstructured":"Takashima T, Mukai H, Hara F, et al. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2016;17:90\u20138.","journal-title":"Lancet Oncol."},{"key":"580_CR21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53\u201372.","journal-title":"Health Policy."},{"key":"580_CR22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst."},{"key":"580_CR23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hec.673","volume":"11","author":"A Tsuchiya","year":"2002","unstructured":"Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341\u201353.","journal-title":"Health Econ."},{"key":"580_CR24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095\u2013108.","journal-title":"Med Care."},{"key":"580_CR25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203\u201320.","journal-title":"Med Care."},{"key":"580_CR26","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf . Accessed 5 Jun 2017."},{"key":"580_CR27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/oso\/9780198524847.003.0012","volume-title":"Analysis of longitudinal data","author":"PJ Diggle","year":"2002","unstructured":"Diggle PJ, Heagerty P, Liang KY, Zeger SL. Time-dependent Covariates. In: Fitzmaurice GM, Laird NM, Ware JH, editors. Analysis of longitudinal data. 2nd ed. New York: Oxford University Press; 2002. p. 245\u201381.","edition":"2"},{"key":"580_CR28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/9781119513469","volume-title":"Applied longitudinal analysis","author":"GM Fitzmaurice","year":"2011","unstructured":"Fitzmaurice GM, Laird NM, Ware JM. Marginal models: introduction and overview. In: Fitzmaurice GM, Laird NM, Ware JH, editors. Applied longitudinal analysis. 2nd ed. Hoboken: Willey; 2011. p. 341\u201352.","edition":"2"},{"key":"580_CR29","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s11136-011-0037-y","volume":"21","author":"EJ Kim","year":"2012","unstructured":"Kim EJ, Ko SK, Kang HY. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Qual Life Res. 2012;21:1193\u2013203.","journal-title":"Qual Life Res."},{"key":"580_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18090","volume":"18","author":"L Longworth","year":"2014","unstructured":"Longworth L, Yang Y, Mulhern B, et al. Use of generic and condition-specific measures of health related quality of life in NICE decision making: a systematic review, statistical modeling and survey. Health Technol Assess. 2014;18:1\u2013224.","journal-title":"Health Technol Assess."},{"key":"580_CR31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s11136-015-1116-2","volume":"25","author":"B Doble","year":"2016","unstructured":"Doble B, Lorgelly P. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms. Qual Life Res. 2016;25:891\u2013911.","journal-title":"Qual Life Res."},{"key":"580_CR32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40273-013-0033-x","volume":"31","author":"FH Shabaruddin","year":"2013","unstructured":"Shabaruddin FH, Chen LC, Elliott RA, Payne K. A systematic review of utility values for chemotherapy-related adverse events. Pharmacoeconomics. 2013;31:277\u201388.","journal-title":"Pharmacoeconomics."},{"key":"580_CR33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/11597720-000000000-00000","volume":"30","author":"LA Prosser","year":"2012","unstructured":"Prosser LA, Grosse SD, Wittenberg E. Health utility elicitation: is there still a role for direct methods? Pharmacoeconomics. 2012;30:83\u20136.","journal-title":"Pharmacoeconomics."},{"key":"580_CR34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/14737167.2016.1146594","volume":"16","author":"M Schwenkglenks","year":"2016","unstructured":"Schwenkglenks M, Matter-Walstra K. Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments. Expert Rev Pharmacoecon Outcomes Res. 2016;16:207\u201319.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"580_CR35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11136-014-0770-0","volume":"24","author":"V Orgeta","year":"2015","unstructured":"Orgeta V, Edwards RT, Hounsome B, et al. The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carers. Qual Life Res. 2015;24:315\u201324.","journal-title":"Qual Life Res."},{"key":"580_CR36","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11136-009-9513-z","volume":"18","author":"T Shiroiwa","year":"2009","unstructured":"Shiroiwa T, Fukuda T, Tsutani K. Health utility scores of colorectal cancer based on societal preference in Japan. Qual Life Res. 2009;18:1095\u2013103.","journal-title":"Qual Life Res."},{"key":"580_CR37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1047-2797(96)00063-4","volume":"6","author":"R Yancik","year":"1996","unstructured":"Yancik R, Havlik RJ, Wesley MN, et al. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol. 1996;6:399\u2013412.","journal-title":"Ann Epidemiol."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0580-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0580-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0580-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T14:47:05Z","timestamp":1750949225000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0580-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0580-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]}}}